Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.352 EUR | +3.70% | -1.74% | -39.49% |
Business Summary
- products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries;
- diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;
- hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;
- other (3.1%): primarily intermediate biological products and subcontracted manufacturing services.
Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Number of employees: 23,000
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharma
84.3
%
| 5,005 | 82.5 % | 5,558 | 84.3 % | +11.05% |
Diagnostic
10.2
%
| 671 | 11.1 % | 670 | 10.2 % | -0.15% |
Others
3.1
%
| 250 | 4.1 % | 203 | 3.1 % | -18.67% |
Bio Supplies
2.4
%
| 146 | 2.4 % | 160 | 2.4 % | +9.50% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Canada
59.1
%
| 3,856 | 63.6 % | 3,899 | 59.1 % | +1.12% |
Rest of World
21.8
%
| 1,176 | 19.4 % | 1,437 | 21.8 % | +22.19% |
Rest of European Union
13.5
%
| 712 | 11.7 % | 893 | 13.5 % | +25.50% |
Spain
5.5
%
| 321 | 5.3 % | 363 | 5.5 % | +13.18% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nacho Abia
CEO | Chief Executive Officer | 55 | Feb. 05 |
Director of Finance/CFO | 67 | 06-12-31 | |
Chairman | 65 | 06-04-04 | |
Albert Coma-Cros
CTO | Chief Tech/Sci/R&D Officer | - | 03-12-31 |
Director/Board Member | 68 | 00-04-12 | |
Investor Relations Contact | 61 | 95-12-31 | |
Comptroller/Controller/Auditor | 45 | 15-12-31 | |
Human Resources Officer | 58 | 21-06-30 | |
Corporate Officer/Principal | 54 | 00-12-31 | |
David Bell
LAW | General Counsel | 70 | 03-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 65 | 06-04-04 | |
Director/Board Member | 68 | 00-04-12 | |
Director/Board Member | 59 | 15-05-28 | |
Director/Board Member | 56 | 15-05-28 | |
James Costos
BRD | Director/Board Member | 61 | 20-10-08 |
Nacho Abia
CEO | Chief Executive Officer | 55 | Feb. 05 |
Director/Board Member | 59 | 19-05-23 | |
Albert Coma-Cros
CTO | Chief Tech/Sci/R&D Officer | - | 03-12-31 |
Director/Board Member | - | 22-06-09 | |
Director/Board Member | 47 | 22-06-09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 261,425,110 | 256,906,911 ( 98.27 %) | 4,518,199 ( 1.728 %) | 75.84 % |
Stock B | 1 | 426,129,798 | 264,542,564 ( 62.08 %) | 3,944,430 ( 0.9256 %) |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
437,069,656 | 6.49% | 428,380,711 $ |
Company contact information
Grifols SA
Avinguda de la Generalitat, 152-158 Parc de Negocis Can Sant Joan
08174, Barcelona
+34 935 712 200
http://www.grifols.comGroup companies
Name | Category and Sector |
---|---|
Squadron Reinsurance DAC
Squadron Reinsurance DAC Multi-Line InsuranceFinance Part of Grifols SA, Squadron Reinsurance DAC is an Irish company that provides reinsurance services. The company is based in Dublin, Ireland. |
Multi-Line Insurance
|
Gri-Cel SA
Gri-Cel SA Financial ConglomeratesFinance Part of Grifols SA, Gri-Cel SA provides investment services. The company is based in Barcelona, Spain. The CEO of the Spanish company is Dirk Büscher. |
Financial Conglomerates
|
Grifols India Healthcare Pvt Ltd.
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.49% | 5.87B | |
-1.54% | 91.26B | |
-2.37% | 38.17B | |
+71.42% | 26.74B | |
-12.31% | 15.93B | |
-4.54% | 13.37B | |
-10.83% | 11.77B | |
+180.20% | 10.92B | |
-48.60% | 10.27B | |
+1.42% | 8.69B |
- Stock Market
- Equities
- GRF Stock
- Company Grifols, S.A.